Vincenzo Stanghellini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7448714/publications.pdf

Version: 2024-02-01

			34016	22764
ı	149	13,209	52	112
	papers	citations	h-index	g-index
	150	150	1.50	0717
	153	153	153	8717
	all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Role of inflammation in pediatric irritable bowel syndrome. Neurogastroenterology and Motility, 2023, 35, e14365.	1.6	7
2	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. American Journal of Gastroenterology, 2022, 117, 147-157.	0.2	39
3	Pathophysiology and Clinical Management of Bile Acid Diarrhea. Journal of Clinical Medicine, 2022, 11, 3102.	1.0	8
4	Pathophysiology of Diverticular Disease: From Diverticula Formation to Symptom Generation. International Journal of Molecular Sciences, 2022, 23, 6698.	1.8	15
5	The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. Age and Ageing, 2021, 50, 498-504.	0.7	1
6	Implications of SARSâ€CoVâ€2 infection for neurogastroenterology. Neurogastroenterology and Motility, 2021, 33, e14104.	1.6	45
7	SeHCAT test for bile acid malabsorption: may "the old―become "the gold one―in the diagnostic burden of chronic diarrhea?. Clinical and Translational Imaging, 2021, 9, 177-180.	1.1	O
8	Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry. Acta Diabetologica, 2021, 58, 1225-1236.	1.2	6
9	Evidence of enteric angiopathy and neuromuscular hypoxia in patients with mitochondrial neurogastrointestinal encephalomyopathy. American Journal of Physiology - Renal Physiology, 2021, 320, G768-G779.	1.6	9
10	Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier. Frontiers in Nutrition, 2021, 8, 718356.	1.6	98
11	Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review with Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-9.	0.8	30
12	Pain and Frailty in Hospitalized Older Adults. Pain and Therapy, 2020, 9, 727-740.	1.5	22
13	Non-Celiac Gluten Sensitivity in the Context of Functional Gastrointestinal Disorders. Nutrients, 2020, 12, 3735.	1.7	34
14	European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVIDâ€19 pandemic. Neurogastroenterology and Motility, 2020, 32, e13930.	1.6	15
15	Mast cellâ€nerve interactions correlate with bloating and abdominal pain severity in patients with nonâ€celiac gluten / wheat sensitivity. Neurogastroenterology and Motility, 2020, 32, e13814.	1.6	21
16	Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity. Gut, 2020, 69, 1966-1974.	6.1	49
17	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. European Journal of Internal Medicine, 2019, 68, e7-e11.	1.0	2
18	µâ€opioid receptor, βâ€endorphin, and cannabinoid receptorâ€2 are increased in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterology and Motility, 2019, 31, e13688.	1.6	25

#	Article	IF	CITATIONS
19	Enteric neuron density correlates with clinical features of severe gut dysmotility. American Journal of Physiology - Renal Physiology, 2019, 317, G793-G801.	1.6	15
20	Pyridostigmine in Pediatric Intestinal Pseudo-obstruction: Case Report of a 2-year Old Girl and Literature Review. Journal of Neurogastroenterology and Motility, 2019, 25, 508-514.	0.8	11
21	Gastroparesis: a turning point in understanding and treatment. Gut, 2019, 68, 2238-2250.	6.1	144
22	Gut epithelial and vascular barrier abnormalities in patients with chronic intestinal pseudoâ€obstruction. Neurogastroenterology and Motility, 2019, 31, e13652.	1.6	6
23	Nerve fiber overgrowth in patients with symptomatic diverticular disease. Neurogastroenterology and Motility, 2019, 31, e13575.	1.6	14
24	Is gastroparesis a gastric disease?. Neurogastroenterology and Motility, 2019, 31, e13562.	1.6	34
25	Allergic Proctocolitis Is a Risk Factor for Functional Gastrointestinal Disorders in Children. Journal of Pediatrics, 2018, 195, 128-133.e1.	0.9	26
26	Functional variants in the sucrase–isomaltase gene associate with increased risk of irritable bowel syndrome. Gut, 2018, 67, 263-270.	6.1	120
27	Effect of <i>Lactobacillus paracasei</i> CNCM lâ€1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United European Gastroenterology Journal, 2018, 6, 604-613.	1.6	77
28	Recent advances in understanding non-celiac gluten sensitivity. F1000Research, 2018, 7, 1631.	0.8	40
29	Gastroparesis. Nature Reviews Disease Primers, 2018, 4, 41.	18.1	235
30	Fecal Clostridiales distribution and short hain fatty acids reflect bowel habits in irritable bowel syndrome. Environmental Microbiology, 2018, 20, 3201-3213.	1.8	59
31	The stomach and obesity: the missing link, at last?. The Lancet Gastroenterology and Hepatology, 2017, 2, 842-843.	3.7	1
32	Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United European Gastroenterology Journal, 2017, 5, 773-788.	1.6	81
33	Benign Pancreatic Hyperenzymemia. Pancreas, 2017, 46, 5-7.	0.5	5
34	Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV. Digestive Diseases, 2017, 35, 14-17.	0.8	48
35	Diagnostic challenges of symptomatic uncomplicated diverticular disease. Minerva Gastroenterology, 2017, 63, 119-129.	0.3	11
36	Acute abdominal pain in the emergency department of a university hospital in Italy. United European Gastroenterology Journal, 2016, 4, 297-304.	1.6	29

#	Article	IF	CITATIONS
37	Gastroduodenal Disorders. Gastroenterology, 2016, 150, 1380-1392.	0.6	1,088
38	Prucalopride exerts neuroprotection in human enteric neurons. American Journal of Physiology - Renal Physiology, 2016, 310, G768-G775.	1.6	34
39	Nickel sensitization in patients with gastroâ€esophageal reflux disease. United European Gastroenterology Journal, 2016, 4, 184-190.	1.6	7
40	Variants of the ACTG2 gene correlate with degree of severity and presence of megacystis in chronic intestinal pseudo-obstruction. European Journal of Human Genetics, 2016, 24, 1211-1215.	1.4	43
41	Features and Progression of Potential Celiac Disease in Adults. Clinical Gastroenterology and Hepatology, 2016, 14, 686-693.e1.	2.4	65
42	Interferon- \hat{I}^3 is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. American Journal of Physiology - Renal Physiology, 2016, 310, G439-G447.	1.6	40
43	Randomised controlled trial of mesalazine in IBS. Gut, 2016, 65, 82-90.	6.1	91
44	Chronic constipation in the elderly: a primer for the gastroenterologist. BMC Gastroenterology, 2015, 15, 130.	0.8	122
45	Quantification and Potential Functions of Endogenous Agonists of Transient Receptor Potential Channels in Patients With Irritable Bowel Syndrome. Gastroenterology, 2015, 149, 433-444.e7.	0.6	116
46	Nerve Fiber Outgrowth Is Increased in the Intestinal Mucosa of Patients With Irritable Bowel Syndrome. Gastroenterology, 2015, 148, 1002-1011.e4.	0.6	127
47	Mutations in RAD21 Disrupt Regulation of APOB in Patients With Chronic Intestinal Pseudo-Obstruction. Gastroenterology, 2015, 148, 771-782.e11.	0.6	71
48	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut, 2015, 64, 1774-1782.	6.1	97
49	Liver as a Source for Thymidine Phosphorylase Replacement in Mitochondrial Neurogastrointestinal Encephalomyopathy. PLoS ONE, 2014, 9, e96692.	1.1	42
50	Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation. United European Gastroenterology Journal, 2014, 2, 138-147.	1.6	56
51	A 5-Year Experience of Benign Pancreatic Hyperenzymemia. Pancreas, 2014, 43, 874-878.	0.5	15
52	Inflammatory bowel disease and irritable bowel syndrome. Current Opinion in Gastroenterology, 2014, 30, 352-358.	1.0	53
53	Clinical features of constipation in general practice in Italy. United European Gastroenterology Journal, 2014, 2, 232-238.	1.6	18
54	Tinnitus in patients on therapy with proton pump inhibitors (PPI) and in PPI non-users. Hearing, Balance and Communication, 2014, 12, 84-87.	0.1	2

#	Article	IF	CITATIONS
55	Gastroparesis: separate entity or just a part of dyspepsia?. Gut, 2014, 63, 1972-1978.	6.1	128
56	Review article: adherence to Rome criteria in therapeutic trials in functional dyspepsia. Alimentary Pharmacology and Therapeutics, 2014, 40, 435-466.	1.9	9
57	Salmonella Gastroenteritis During Childhood Is a Risk Factor for Irritable Bowel Syndrome in Adulthood. Gastroenterology, 2014, 147, 69-77.	0.6	77
58	Perspectives on irritable bowel syndrome: where have we been? Where are we now?. Expert Review of Gastroenterology and Hepatology, 2013, 7, 3-7.	1.4	3
59	Expression and regulation of αâ€ŧransducin in the pig gastrointestinal tract. Journal of Cellular and Molecular Medicine, 2013, 17, 466-474.	1.6	19
60	Audit of digestive complaints and psychopathological traits in patients with eating disorders: A prospective study. Digestive and Liver Disease, 2013, 45, 639-644.	0.4	55
61	Current management strategies and emerging treatments for functional dyspepsia. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 187-194.	8.2	155
62	Contrast-Enhanced Ultrasound in the Differential Diagnosis of Exocrine Versus Neuroendocrine Pancreatic Tumors. Pancreas, 2013, 42, 871-877.	0.5	31
63	Detection of anticonductive tissue autoantibodies in a patient with chronic intestinal pseudo-obstruction and sick sinus syndrome. European Journal of Gastroenterology and Hepatology, 2013, 25, 1358-1363.	0.8	2
64	Fiber and macrogol in the therapy of chronic constipation. Minerva Gastroenterologica E Dietologica, 2013, 59, 217-30.	2.2	4
65	Sigmoid compliance and visceral perception in spinal cord injury patients. European Journal of Gastroenterology and Hepatology, 2012, 24, 340-345.	0.8	8
66	Genetics of human enteric neuropathies. Progress in Neurobiology, 2012, 96, 176-189.	2.8	36
67	Does colorectal endometriosis alter intestinal functions? A prospective manometric and questionnaire-based study. Fertility and Sterility, 2012, 97, 652-656.	0.5	39
68	Unfulfilled Wishes by Gastric Electrical Stimulation. Clinical Gastroenterology and Hepatology, 2011, 9, 447-448.	2.4	10
69	Intestinal Serotonin Release, Sensory Neuron Activation, and Abdominal Pain in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2011, 106, 1290-1298.	0.2	179
70	Chronic Intestinal Pseudo-Obstruction: Clinical Features, Diagnosis, and Therapy. Gastroenterology Clinics of North America, 2011, 40, 787-807.	1.0	118
71	The Immune System in Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility, 2011, 17, 349-359.	0.8	171
72	Mechanisms Underlying Visceral Hypersensitivity in Irritable Bowel Syndrome. Current Gastroenterology Reports, 2011, 13, 308-315.	1.1	109

#	Article	IF	CITATIONS
73	Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon?. Expert Review of Molecular Diagnostics, 2010, 10, 389-393.	1.5	19
74	Autoimmune Hepatitis and Celiac Disease: Case Report Showing an Entero-Hepatic Link. Case Reports in Gastroenterology, 2010, 4, 469-475.	0.3	4
75	Natural History of Intestinal Failure Induced by Chronic Idiopathic Intestinal Pseudo-Obstruction. Transplantation Proceedings, 2010, 42, 15-18.	0.3	44
76	Biomarkers in IBS: when will they replace symptoms for diagnosis and management?. Gut, 2009, 58, 1571-1575.	6.1	32
77	Aminosalicylates and Other Anti-Inflammatory Compounds for Irritable Bowel Syndrome. Digestive Diseases, 2009, 27, 115-121.	0.8	23
78	Neurogenic Chronic Intestinal Pseudo-Obstruction: Antineuronal Antibody-Mediated Activation of Autophagy Via Fas. Gastroenterology, 2008, 135, 601-609.	0.6	21
79	How Relevant Is Symptom Evaluation in NERD?. Digestion, 2008, 78, 11-16.	1.2	0
80	A Mutation in Telethonin Alters Nav1.5 Function. Journal of Biological Chemistry, 2008, 283, 16537-16544.	1.6	59
81	Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis. Expert Review of Gastroenterology and Hepatology, 2008, 2, 735-740.	1.4	9
82	A Case of Paraneoplastic Inflammatory Neuropathy of the Gastrointestinal Tract Related to an Underlying Neuroblastoma: Successful Management With Immunosuppressive Therapy. Journal of Pediatric Gastroenterology and Nutrition, 2008, 46, 457-460.	0.9	6
83	Probiotics and Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2008, 42, S214-S217.	1.1	25
84	Chronic intestinal pseudo-obstruction. World Journal of Gastroenterology, 2008, 14, 2953.	1.4	195
85	A mutation in telethonin alters Nav1.5 function. VOLUME 283 (2008) PAGES 16537-16544. Journal of Biological Chemistry, 2008, 283, 22336.	1.6	0
86	Almost All Irritable Bowel Syndromes Are Post-Infectious and Respond to Probiotics: Controversial Issues. Digestive Diseases, 2007, 25, 245-248.	0.8	21
87	Overlap Between GERD and IBS. Journal of Clinical Gastroenterology, 2007, 41, S114-S117.	1.1	9
88	Determination of ReQuest TM -Based Symptom Thresholds to Define Symptom Relief in GERD Clinical Studies. Digestion, 2007, 75, 55-61.	1.2	8
89	Mast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome. Gastroenterology, 2007, 132, 26-37.	0.6	668
90	Chronic intestinal pseudo-obstruction. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 657-669.	1.0	37

#	Article	IF	Citations
91	Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterology and Motility, 2007, 19, 440-452.	1.6	158
92	A novel locus for syndromic chronic idiopathic intestinal pseudo-obstruction maps to chromosome 8q23–q24. European Journal of Human Genetics, 2007, 15, 889-897.	1.4	29
93	Transcriptional regulation of TLX2 and impaired intestinal innervation: possible role of the PHOX2A and PHOX2B genes. European Journal of Human Genetics, 2007, 15, 848-855.	1.4	22
94	Sympathetic hyperactivity in patients with ulcerative colitis. Clinical Autonomic Research, 2007, 17, 217-220.	1.4	22
95	Functional Gastroduodenal Disorders. Gastroenterology, 2006, 130, 1466-1479.	0.6	1,740
96	Neuroplasticity of the Enteric Nervous System Induced by Inflammatory Conditions of the Gut. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, S7-S8.	0.9	0
97	Enteric neuropathology of congenital intestinal obstruction: A case report. World Journal of Gastroenterology, 2006, 12, 5229-33.	1.4	10
98	Idiopathic dyspepsia. Current Treatment Options in Gastroenterology, 2005, 8, 175-183.	0.3	2
99	Natural History of Chronic Idiopathic Intestinal Pseudo-Obstruction in Adults: A Single Center Study. Clinical Gastroenterology and Hepatology, 2005, 3, 449-458.	2.4	176
100	Interactions Between Commensal Bacteria and Gut Sensorimotor Function in Health and Disease. American Journal of Gastroenterology, 2005, 100, 2560-2568.	0.2	291
101	Determination of ReQuestâ,,¢-Based Symptom Thresholds to Define Symptom Relief in GERD Clinical Studies. Digestion, 2005, 71, 145-151.	1.2	26
102	Prevalence and Socioeconomic Impact of Upper Gastrointestinal Disorders in the United States: Results of the US Upper Gastrointestinal Study. Clinical Gastroenterology and Hepatology, 2005, 3, 543-552.	2.4	339
103	ReQuest: new dimensions in the assessment and management of GERD. Drugs of Today, 2005, 41 Suppl B, 7-11.	0.7	5
104	The Construction of a New Evaluative GERD Questionnaire – Methods and State of the Art. Digestion, 2004, 70, 71-78.	1.2	36
105	Intestinal Transplantation for Chronic Intestinal Pseudo-Obstruction in Adult Patients. American Journal of Transplantation, 2004, 4, 826-829.	2.6	53
106	Gastroparesis Cardinal Symptom Index (GCSI): Development and validation of a patient reported assessment of severity of gastroparesis symptoms. Quality of Life Research, 2004, 13, 833-844.	1.5	311
107	Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: The PAGI-QOL�. Quality of Life Research, 2004, 13, 1751-1762.	1.5	110
108	Delayed gastric emptying in functional dyspepsia. Current Treatment Options in Gastroenterology, 2004, 7, 259-264.	0.3	13

#	Article	IF	CITATIONS
109	ReQuestâ,,¢â€" the challenge of quantifying both esophageal and extra-esophageal manifestations of GERD. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 27-30.	1.0	12
110	Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders. Clinical Gastroenterology and Hepatology, 2004, 2, 778-786.	2.4	45
111	Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clinical Gastroenterology and Hepatology, 2004, 2, 769-777.	2.4	79
112	Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology, 2004, 126, 693-702.	0.6	1,246
113	Inflammatory neuropathies of the enteric nervous systemâ~†. Gastroenterology, 2004, 126, 1872-1883.	0.6	265
114	Prokinetics in the treatment of acute intestinal pseudo-obstruction. IDrugs: the Investigational Drugs Journal, 2004, 7, 160-5.	0.7	3
115	New Developments in the Treatment of Functional Dyspepsia. Drugs, 2003, 63, 869-892.	4.9	37
116	The Rome II Criteria for Patients With Functional Gastroduodenal Disorders. Journal of Clinical Gastroenterology, 2003, 37, 92-93.	1.1	5
117	GERD 2003 – A Consensus on the Way Ahead. Digestion, 2003, 67, 111-117.	1.2	41
118	Dyspeptic symptoms and gastric emptying in the irritable bowel syndrome. American Journal of Gastroenterology, 2002, 97, 2738-2743.	0.2	79
119	Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. American Journal of Gastroenterology, 2002, 97, 2454-2459.	0.2	91
120	Dyspeptic symptoms in primary care. An observational study in general practice. European Journal of Gastroenterology and Hepatology, 2002, 14, 985-990.	0.8	32
121	Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. American Journal of Gastroenterology, 2002, 97, 2454-2459.	0.2	76
122	HOX11L1: a promoter study to evaluate possible expression defects in intestinal motility disorders. International Journal of Molecular Medicine, 2002, 10, 101-6.	1.8	22
123	Helicobacter pylori infection and gastric function in patients with fundic atrophic gastritis. Digestive Diseases and Sciences, 2001, 46, 1573-1583.	1.1	20
124	Idiopathic myenteric ganglionitis underlying intractable vomiting in a young adult. European Journal of Gastroenterology and Hepatology, 2000, 12, 613-616.	0.8	51
125	Gastric emptying and dyspeptic symptoms in patients with nonautoimmune fundic atrophic gastritis. Digestive Diseases and Sciences, 2000, 45, 252-257.	1.1	29
126	Assessment of gastric emptying using a low fat meal: establishment of international control values. American Journal of Gastroenterology, 2000, 95, 1456-1462.	0.2	611

#	Article	IF	Citations
127	Reduced Bcl-2 expression in the enteric nervous system (ENS) as a marker for neural degeneration in patients with gastrointestinal motor disorders (GIMD). Gastroenterology, 2000, 118, A867.	0.6	11
128	Predominant Symptoms Identify Different Subgroups in Functional Dyspepsia. American Journal of Gastroenterology, 1999, 94, 2080-2085.	0.2	92
129	Esophageal and gastric nitric oxide synthesizing innervation in primary achalasia. American Journal of Gastroenterology, 1999, 94, 2357-2362.	0.2	62
130	Risk indicators of organic diseases in uninvestigated dyspepsia. European Journal of Gastroenterology and Hepatology, 1999, 11, 1129-1134.	0.8	17
131	1 Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: Clarifying the concepts. Bailliere's Clinical Gastroenterology, 1998, 12, 417-433.	0.9	41
132	Detection of substance P immunoreactivity in human peripheral leukocytes. Journal of Neuroimmunology, 1998, 82, 175-181.	1.1	54
133	Roundtable discussion: Differences between Japan and Western countries in the treatment of dyspepsia. Clinical Therapeutics, 1998, 20, D23-D32.	1.1	0
134	Management of Dyspepsia in General Practice. Pharmacoeconomics, 1998, 14, 57-66.	1.7	5
135	Reversal of Fundic Atrophy After Eradication of Helicobacter pylori. American Journal of Gastroenterology, 1998, 93, 1425-1431.	0.2	95
136	Widespread Eradication of Helicobacter pylori: A Debate. Helicobacter, 1997, 2, 77-80.	1.6	3
137	Ambulatory intestinal manometry: a consensus report on its clinical role. Digestive Diseases and Sciences, 1997, 42, 2395-2400.	1.1	43
138	Upper gastrointestinal motor activity in patients with slow-transit constipation. Digestive Diseases and Sciences, 1996, 41, 1999-2005.	1.1	83
139	Feedback regulation and sensation. Digestive Diseases and Sciences, 1994, 39, 124S-127S.	1.1	5
140	Effects of Acute Cold Pressor Test on Vagally Stimulated Gastric Acid Secretion and Circulating Levels of Human Pancreatic Polypeptide and Gastrin. Digestion, 1994, 55, 154-159.	1.2	3
141	One-day therapy for treatment ofHelicobacter pylori infection. Digestive Diseases and Sciences, 1993, 38, 1670-1673.	1.1	52
142	Evaluation of gastrointestinal innervation in humans. Journal of the Autonomic Nervous System, 1993, 43, 5.	1.9	1
143	Fat-induced heal brake in humans: A dose-dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology, 1993, 105, 733-739.	0.6	187
144	Asymptomatic Peptic Ulcer Disease. Drugs, 1991, 41, 821-824.	4.9	4

#	Article	IF	CITATIONS
145	Gastric acid secretion and gastric emptying of liquids in 99 male duodenal ulcer patients. Digestive Diseases and Sciences, 1989, 34, 251-256.	1.1	16
146	12 Pseudo-obstruction syndromes. Bailliere's Clinical Gastroenterology, 1988, 2, 225-254.	0.9	44
147	Gastrointestinal motility disturbances in patients with orthostatic hypotension. Gastroenterology, 1985, 88, 1852-1859.	0.6	86
148	Manometric Evaluation of Functional Upper Gut Symptoms. Gastroenterology, 1985, 88, 1223-1231.	0.6	338
149	Gastric secretion and emptying of liquids in reflux esophagitis. Digestive Diseases and Sciences, 1981, 26, 886-889.	1.1	52